Developent of glycolipid vaccines against tuberculos is

检测致病分枝杆菌通过利用宿主来源的葡萄糖生物合成的葡萄糖单霉菌酸盐在豚鼠中诱导特异性T细胞应答的能力。这是第一次表明，糖脂类物质能够引起致敏动物的迟发型超敏反应。此外，葡萄糖单胞菌酸盐诱导的T细胞反应高度偏向于保护性TH1型细胞因子的产生。因此，这些结果强调了葡萄糖单霉菌酸酯可以作为一种新型的抗结核疫苗的可能性。

Glucose monomycolate that pathogenic mycobacteria biosynthesize by utilizing host-derived glucose was tested for its ability to induce specific T cell responses in guinea pigs. It was shown for the first time that the glycolipid species was capable of eliciting delayed-type hypersensitivity in sensitized animals. Furthermore, the glucose monomycolate-induced T cell response was highly skewed to the production of the protective TH1-type cytokines. Thus, these results underscored the possibility that glucose monomycolate could function as a novel type of anti-tuberculosis vaccines.